Biosimilar arthritis drug shows Real-World safety in small study
NCT ID NCT03885037
First seen Jan 09, 2026 · Last updated May 19, 2026 · Updated 14 times
Summary
This study looked at how safe and effective a biosimilar version of infliximab (a drug that blocks inflammation) is for people with rheumatoid arthritis. 77 patients were treated and monitored for side effects and changes in disease activity. The goal was to gather real-world information on this treatment option.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pfizer Local Country Office
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.